Suraj Padhiar

• Advised BeOne Medicines, the Nasdaq-listed biotech company, on a pioneering financing comprising a Renminbi-denominated term loan facility of ¥2.15 billion, alongside a U.S. dollar-denominated term loan facility of US$560 million, and U.S. dollar-denominated revolving loan facility of US$140 million.
• Advised Nomad Foods Group, Europe’s leading frozen food business, on the refinancing of its term loan B facilities of US$620 million and €880 million, and its multicurrency revolving credit facility of €175 million.
• Represented Ono Pharmaceutical Co., Ltd., a Japanese company (kabushiki kaisha), on its cash tender offer followed by a merger of U.S. biopharmaceutical company Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH) for a total equity value of $2.4 billion.
• Advised a major integrated insurance and investment management firm on a high-profile funded sub-participation relating to financing provided to a Premier League football club. Further advised the same client on a range of matters on the debt finance, enforcement and solvent restructuring aspects of a broader portfolio of sports sector investments.
• Advised a global investment bank on the structuring and documentation of a US$295 million loan for a listed music rights investment trust, secured against a global portfolio of copyrights and performance royalty streams.
• Acted for a leading institutional credit fund in relation to structured debt participation within the UK sports media and entertainment sector, involving Premier League and EFL Championship entities.
• Advised a global specialist investment firm on the legal and structural implications of its acquisition by a tier-one international financial services group. Provided strategic counsel on the integration of its UK and European lending platforms and managed the transfer of asset management mandates during the majority change-of-control.
• Advised a leading alternative lender on the implementation of a number of bespoke investment frameworks for off-balance sheet assets.
• Advised Hilco Capital in relation to its acquisition of Design Group Americas, Inc.
• Advised Cheyne SVC on its private credit investment in LuxVet Group.
• Advised SEGASammy Holdings in relation to English law aspects of its investment and provision of debt financing into a US-based online gaming business.
• Advised the European Investment Bank (EIB) on the debt finance aspects of its funding to Northvolt and subsequent Chapter 11 bankruptcy proceedings
• Advised Oxford Finance, a specialist non-bank lender in the life sciences, pharmaceutical and health care services sectors, on various English law financings of up to US$400 million provided to companies in the life sciences, pharmaceuticals and healthcare sectors.
• Advised InPost, Europe’s leading automated parcel machine service provider, on the debt finance aspects of its acquisition of an equity stake in Menzies Distribution Group Limited, and the subsequent financing in connection with the acquisition of the Menzies Express and Newstrade operations.
• Advised Terra Firma, a leading European private equity house on the strategic reorganisation and sale of the Wyevale Garden Centres group (formerly the largest garden centre operator in the UK), involving the sale of 145 sites across over 50 transactions.°
• Advised Piper Private Equity on its successful exit of Be At One to Stonegate Pub Company.°
• Advised McMakler, a leading property technology (PropTech) company in the German real estate market, on numerous financing rounds, including most recently led by Kreos Capital, a BlackRock-backed lender, alongside Target Global.
• Advised luxury senior-living operator Auriens on its recapitalisation by Oaktree Capital, including the amendment and restatement of its £184mn senior financing.

°The above representations were handled by Mr. Padhiar prior to his joining Greenberg Traurig, LLP.

• Listed, The Legal 500 United Kingdom, Bank Lending: Investment Grade Debt and Syndicated Loans, 2026